I. AMENDMENTS

Please cancel claim 1. Please add new claims 2 to 14 as follows:

2. A method of detecting a cell proliferative disorder, comprising contacting a GDF-5 specific antibody, or an antigen binding fragment of a GDF-5 specific antibody, with a specimen of a subject suspected of having a GDF-5 associated disorder, and detecting binding of the antibody or the antigen binding fragment of the antibody.

3. The method of claim 2, wherein the cell proliferative disorder is a uterine neoplasm or endometriosis.

4. The method of claim 2, wherein the cell proliferative disorder is a skeletal disorder.

5. The method of claim 2, wherein the detecting is *in vivo*.

6. The method of claim 2, wherein the detection is *in vitro*.

7. The method of claim 2, wherein the antibody comprises a detectable label.

8. The method of claim 7, wherein the detectable label is a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, an enzyme, a colloidal metal, a phosphorescent compound, or a paramagnetic isotope.

9. The method of claim 2, wherein the antibody comprises a hapten coupled thereto.

10. The method of claim 9, wherein the hapten is biotin, dinitrophenyl, puridoxal, or fluorescein.

11. The method of claim 2, wherein the antibody is a monoclonal antibody.

12. The method of claim 2, wherein the antigen binding fragment of the GDF-5 specific antibody is an Fab fragment or an $F(ab')_2$ fragment.

13. The method of claim 2, wherein the antibody or antigen binding fragment of the antibody is bound to a solid phase carrier.

14. The method of claim 11, wherein the solid phase carrier comprises glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylase, natural cellulose, modified cellulose, polyacrylamide, agarose or magnetite.--